Scott Rocklage, Ph.D., is the Managing Partner at 5AM Ventures, a company he first joined in 2003. Dr. Scott Rocklage has had a long career that involves several research and development positions in the medical field as well as years of experience as a top executive. His work has led to the FDA approval of three drugs that he oversaw the development of; Cubicin, Teslascan, and Omniscan. He also holds more than 30 U.S. patents and has published more than 100 research papers that have been published in several peer-reviewed medical journals.
Dr. Scott Rocklage has held a variety of r&d positions at pharmaceutical companies including Catalytica and Salutar. He has also held executive level positions at several biotechnology companies. This includes Cubist Pharmaceuticals where he was the Chairman of the Board and Chief Executive Officer. He has also been the CEO and President of Nycomed Salutar, and Chairman of the Board at Relypsa as well as Novira. Among the corporate boards that Dr. Rocklage currently serves on are those of Cidara, Epirus, Kinestral, and Rennovia.
Dr. Rocklage has explained that 5AM Ventures got its name because it invests in startup pharmaceutical companies. Being 5AM is a very early time of the day a name that incorporated it fit with the concept of the investment firm. He has also said that he sometimes even gets up that early to meet the busy demands of his workdays. Every day is different and might involve research, meeting with portfolio management teams, or other days involving board meetings for the various companies he serves in that capacity and Scott of Linkedin.
One of the areas that most interests Dr. Scott Rocklage is the research that is being done on cancer. New techniques involve targeting specific mutations in order to treat cancer which he sees as extremely promising. These techniques are now already being used to treat cancer and improve patient outcomes and what Scott knows.
As an entrepreneur, Dr. Rocklage has offered his advice to others. First, he says don’t be afraid to go out on your own instead of being tied to a Fortune 500 company. He also says to stay true to yourself and play off of your strengths and read full article.